IL6 and neoplasm: We speculate that in the context of active immunotherapy-driven tumor destruction, blocking IL-6 signaling might compromise the potential therapeutic advantages associated with high baseline TGFβ-specific immunity in patients with PDAC receiving immune checkpoint inhibition and radiotherapy.